News and Press Releases

All | News | Press | Recruitment

Recent | Archive

Valo Therapeutics appoints Carlos de Sousa as Chief Executive Officer

Helsinki, Finland; Naples, Italy – 21 August 2026 – Valo Therapeutics Group (“Valo Therapeutics”), a clinical-stage biotechnology company developing novel immunotherapies for cancer, announced the appointment of Carlos de Sousa, MD, MBA, as Chief Executive Officer of Valo Therapeutics Group. Carlos is a senior biopharmaceutical executive and business leader with extensive international experience across biotechnology, pharmaceuticals, oncology, immunotherapy, business development, licensing, mergers and acquisitions, corporate strategy and medical affairs. Throughout his career, Carlos has held CEO, President, Chief Business Officer

21/8/26

Press Release

Valo Therapeutics Oy announces first patient dosed in Italy with PeptiCRAd-1 in the START Phase I clinical trial at Candiolo Cancer Institute, FPO-IRCCS in Turin

Turin, Italy ; Helsinki, Finland – June 8th 2026 – Valo Therapeutics Oy, a clinical-stage biotechnology company developing next-generation cancer immunotherapies, announced that the first patient has been dosed with PeptiCRAd-1 in the ongoing Phase I START clinical trial at Candiolo Cancer Institute, FPO-IRCCS, Italy. The START study is evaluating the safety, tolerability, and preliminary anti-tumor activity of PeptiCRAd-1 in patients with advanced solid tumors, including in combination with pembrolizumab. The trial explores innovative administration strategies, including intratumoral and subcutaneous

8/6/26

Press Release

Valo Therapeutics Announces Interim Phase 1 Clinical Data for PeptiCRAd-1 to Be Presented at ASCO 2026

Interim VALO-001 results demonstrate encouraging safety profile, tumor-specific immune activation, and early clinical responses in advanced solid tumors Valo Therapeutics announced that interim clinical data from the Phase 1 VALO-001 trial evaluating PeptiCRAd-1, the company’s modular oncolytic adenovirus vaccine platform targeting NY-ESO-1 and MAGE-A3, will be presented at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) . The presentation, titled “Clinical translation of PeptiCRAd-1: Interim clinical evaluation of a modular oncolytic adenovirus vaccine platform targeting NY-ESO-1

1/6/26

Press Release

Valo Therapeutics Advances Phase I START Trial Following PEI Approval of Substantial Modification

April 20, 2026 – Valo Therapeutics, a clinical-stage biotechnology company focused on next-generation cancer immunotherapies, today announced that the Paul-Ehrlich-Institut (PEI) has granted approval for a substantial modification to its ongoing Phase I START clinical trial (NCT05492682). The study is investigating the company’s lead immunotherapy candidate, PeptiCRAd-1, in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab. The approved amendment introduces refinements to the clinical protocol, supporting the continued evaluation of PeptiCRAd-1 in patients with injectable solid tumors. In particular, the modification

20/4/26

Press Release

Valo Therapeutics hosts Investigator Meeting in Genoa, Italy for Phase I Clinical Trial of PeptiCRAd-1 in Combination with Pembrolizumab

Genoa, Italy – March 12, 2026 – Valo Therapeutics, a clinical-stage biotechnology company developing next-generation cancer immunotherapies, convened investigators and study teams in Genoa for a meeting supporting the ongoing Phase I START clinical trial (NCT05492682) evaluating PeptiCRAd-1, its proprietary immunotherapeutic platform. The meeting brought together investigators, clinical operations teams, and sponsor representatives from leading oncology centers across Italy to discuss the progress and next steps of the trial, which is evaluating PeptiCRAd-1 in combination with the immune checkpoint inhibitor

18/3/26

Press Release

AIFA Authorizes Clinical Trial of PeptiCRAd-1 in Combination with Pembrolizumab in Italy

Helsinki, Finland / Naples, Italy, 26th January, 2026 Valo Therapeutics Oy (ValoTx), a clinical-stage biotechnology company developing next-generation oncolytic virus–based cancer immunotherapies, announced that the Italian Medicines Agency (AIFA) has authorized the initiation of a Phase I clinical trial evaluating PeptiCRAd-1 in combination with the immune checkpoint inhibitor pembrolizumab in patients with injectable solid tumors in Italy. The authorization follows a positive scientific and ethical assessment conducted through the European clinical trial authorization process and allows Italy to participate as

26/1/26

Press Release

Valo Therapeutics Announces Positive Interim Results from PeptiCRAd-1 Phase 1 Clinical Trial

Helsinki, Finland, 30 June, 2025 – Valo Therapeutics Oy (ValoTx), a clinical-stage biotechnology company developing novel oncolytic virus-based cancer immunotherapies, today announced encouraging interim results from its ongoing Phase 1 clinical trial, START (Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer) — ClinicalTrials.gov ID: NCT05492682 . PeptiCRAd-1 combines tumor-targeting adenoviruses with tumor-specific peptides to stimulate both innate and adaptive immune responses against cancer. Key Interim Findings (Cohort 1): Well tolerated, with no serious treatment-related adverse reactions. Immune activation

30/6/25

Press Release

ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO

Helsinki, Finland and Naples, Italy, 9 April, 2025 – Valo Therapeutics Oy (ValoTx), an immunotherapy company developing novel, adaptable treatments for cancer, today announced the appointment of Marcella Origgi as its Chief Executive Officer (CEO) of its Helsinki headquarters and Naples subsidiary. Marcella joins from Johnson & Johnson Innovation and is an accomplished leader with extensive experience in immuno-oncology, precision medicine, and advanced therapy medicinal products (ATMPs). Marcella’s appointment, based in Italy, comes at a pivotal time for ValoTx, following

8/4/25

Press Release

Valo Therapeutics announces EUR 19m of investment funding and expanded clinical trials

10th March - Helsinki, Finland - Naples, Italy - Perth, Australia Valo Therapeutics Oy announces that it has successfully secured a financing round of €19 million, part of which was raised in Europe and part in Australia, to clinically develop its innovative immune therapy for cancer. An investment round of €13 million was co-led by Indaco Venture Partners and CDP Venture Capital SGR with the support of Fondazione ENEA Tech e Biomedical. They join the completed €6 million investment round

7/3/25

Press Release

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models

6/11/24

Press Release

Leadership Change

Paul Higham recently resigned as CEO of the company and will leave in May to pursue other opportunities. Sari Pesonen, co-founder and currently Chief Scientific Officer, will take over as CEO in early May. Matti Hautsalo commented on behalf of the Board: 'We would like to thank Paul for his service to the company over the past almost 4 years and wish him well for the future. Sari co-founded the company in 2016 and has led the scientific development of

22/4/24

Press Release

Valo Therapeutics Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial into Sarcoma

Four cancer types now included in PeptiCRAd-1 with Pembrolizumab trial: sarcoma, melanoma, triple negative breast cancer and non-small cell lung cancer

28/11/23

Press Release

Valo Therapeutics Announces Acquisition of Bruker Corporation’s Latest Mass Spectrometer Platform for Tumor Antigen Identification with ValoTx’s PeptiCHIP Technology

Top-of-the-Line Molecular Analytics Instrument with Transformative Sensitivity will enable Rapid Identification of Tumor Antigens

10/10/23